Ann: Nyrada Quarterly Activities Report & Appendix 4C, page-5

Yep IMO a bit to look forward to over the next 5 to 6 months (sentiment changed from none to buy):

Pharmacokinetic study expected to report further safety and tolerability data
from higher dose levels over longer duration in the coming weeks

Lead compound NYX-PCSK9i selected and demonstrated efficacy equivalency to
the two FDA approved monoclonal PCSK9 antibody drugs

Interim results from an ongoing in vivo efficacy study of NYX-PCSK9i by the end
of 2020 with final results expected in early 2021

Strong cash position, with A$5.2 million in cash as at 30 September 2020, providing
cash runway until the end of 2021

Nyrada founder and seasoned biotech entrepreneur, Dr Ian Dixon joins the Board as
Non-Executive Director